Home » Topics » Disease categories and therapies » Endocrine/metabolic

Endocrine/metabolic
RSS

ACAT inhibitor reported by Nisshin Flour Milling

April 19, 1996

Human Genome Sciences' research into cathepsin K

April 19, 1996

Fujisawa describes cathepsin L/B inhibitor of fungal origin

April 19, 1996

Cortecs' oral salmon calcitonin shows favorable phase II results

April 19, 1996

Vivus files NDA for Muse

April 12, 1996

Testosterone transdermal patch approved in Sweden

April 12, 1996

Fujisawa in-licenses zenarestat

April 12, 1996

NT-3 shows potential in diabetic neuropathy

April 12, 1996

Selective protein kinase C beta antagonist discovered by Lilly

April 12, 1996

Anergen, Novo Nordisk expand diabetes collaboration

April 12, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for May 13, 2025.
Little bite from voluntary most-favored nation Rx pricing order
BioWorld
After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
AACR 2025: Induced proximity strategy, beyond degraders
BioWorld
Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
China’s NMPA gives thumbs up to Remegen’s ADC targeting HER2
BioWorld
China’s National Medical Products Administration has approved Remegen Co. Ltd.’s antibody-drug conjugate (ADC), disitamab vedotin (RC-48), for treatment of...